Sebelius Kathleen 4
4 · Humacyte, Inc. · Filed Aug 27, 2021
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sebelius Kathleen
Director
Transactions
- Award
Stock Options (right to buy)
2021-08-26+17,068→ 17,068 totalExercise: $6.54Exp: 2028-04-12→ Common Stock (17,068 underlying) - Award
Stock Options (right to buy)
2021-08-26+39,389→ 39,389 totalExercise: $2.56Exp: 2025-09-01→ Common Stock (39,389 underlying)
Footnotes (2)
- [F1]Options are fully vested and exercisable.
- [F2]On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.